IRIS Accounts Production v25.1.3.33 06078259 Board of Directors 30.9.23 29.9.24 29.9.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh060782592023-09-29060782592024-09-29060782592023-09-302024-09-29060782592022-09-30060782592022-10-012023-09-29060782592023-09-2906078259ns15:EnglandWales2023-09-302024-09-2906078259ns14:PoundSterling2023-09-302024-09-2906078259ns10:Director12023-09-302024-09-2906078259ns10:PrivateLimitedCompanyLtd2023-09-302024-09-2906078259ns10:SmallEntities2023-09-302024-09-2906078259ns10:AuditExempt-NoAccountantsReport2023-09-302024-09-2906078259ns10:SmallCompaniesRegimeForDirectorsReport2023-09-302024-09-2906078259ns10:SmallCompaniesRegimeForAccounts2023-09-302024-09-2906078259ns10:FullAccounts2023-09-302024-09-290607825912023-09-302024-09-2906078259ns5:CurrentFinancialInstruments2024-09-2906078259ns5:CurrentFinancialInstruments2023-09-2906078259ns5:ShareCapital2024-09-2906078259ns5:ShareCapital2023-09-2906078259ns5:RetainedEarningsAccumulatedLosses2024-09-2906078259ns5:RetainedEarningsAccumulatedLosses2023-09-2906078259ns10:RegisteredOffice2023-09-302024-09-2906078259ns5:IntangibleAssetsOtherThanGoodwill2023-09-302024-09-2906078259ns5:ComputerSoftware2023-09-302024-09-2906078259ns5:PlantMachinery2023-09-302024-09-2906078259ns5:FurnitureFittings2023-09-302024-09-2906078259ns5:MotorVehicles2023-09-302024-09-2906078259ns5:IntangibleAssetsOtherThanGoodwill2023-09-2906078259ns5:IntangibleAssetsOtherThanGoodwill2024-09-2906078259ns5:IntangibleAssetsOtherThanGoodwill2023-09-2906078259ns5:PlantMachinery2023-09-2906078259ns5:FurnitureFittings2023-09-2906078259ns5:MotorVehicles2023-09-2906078259ns5:PlantMachinery2024-09-2906078259ns5:FurnitureFittings2024-09-2906078259ns5:MotorVehicles2024-09-2906078259ns5:PlantMachinery2023-09-2906078259ns5:FurnitureFittings2023-09-2906078259ns5:MotorVehicles2023-09-2906078259ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-2906078259ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-290607825912023-09-302024-09-29
REGISTERED NUMBER: 06078259 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 29 SEPTEMBER 2024

FOR

MISTRY MEDICAL SUPPLIES LIMITED

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 SEPTEMBER 2024










Page

Statement of Financial Position 1 to 2

Notes to the Financial Statements 3 to 7


MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

STATEMENT OF FINANCIAL POSITION
29 SEPTEMBER 2024

29.9.24 29.9.23
Notes £    £   
FIXED ASSETS
Intangible assets 4 29,416 42,969
Property, plant and equipment 5 26,429 35,243
55,845 78,212

CURRENT ASSETS
Inventories 380,783 334,475
Debtors 6 347,674 400,179
Cash at bank 384,248 459,539
1,112,705 1,194,193
CREDITORS
Amounts falling due within one year 7 (717,248 ) (808,061 )
NET CURRENT ASSETS 395,457 386,132
TOTAL ASSETS LESS CURRENT
LIABILITIES

451,302

464,344

PROVISIONS FOR LIABILITIES (15,754 ) (22,640 )
NET ASSETS 435,548 441,704

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 434,548 440,704
435,548 441,704

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 29 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 29 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

STATEMENT OF FINANCIAL POSITION - continued
29 SEPTEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 June 2025 and were signed on its behalf by:





R A Mistry - Director


MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 SEPTEMBER 2024


1. STATUTORY INFORMATION

MISTRY MEDICAL SUPPLIES LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 06078259

Registered office: Unit 2 Valley Court
Sanderson Way
Midpoint 18
Middlewich
Cheshire
CW10 0GF

The presentation currency of the financial statements is the Pound Sterling (£).


The principal activity of of the company is that of medical supplies.

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

SIGNIFICANT JUDGEMENTS AND ESTIMATES
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

(i) Estimated useful lives and residual values of fixed assets

Depreciation of tangible fixed assets has been based on estimated useful lives and residual
values deemed appropriate by the directors. Estimated useful lives and residual values are
reviewed annually and revised as appropriate. Revisions take into account estimated useful lives
used by other companies operating in the sector and actual asset lives and residual values, as
evidenced by disposals during the current and prior accounting periods.

REVENUE RECOGNITION
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer, usually on despatch of the goods, the amount of revenue can be measured reliably, it is probable that the associated economic benefits will flow to the entity, and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


2. ACCOUNTING POLICIES - continued

INTANGIBLE ASSETS
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Website costs is being amortised evenly over its estimated useful life of five years.

TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 20% reducing balance
Fixtures and fittings - 20% on cost
Motor vehicles - 25% reducing balance

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses.

STOCKS
Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

FINANCIAL INSTRUMENTS
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


2. ACCOUNTING POLICIES - continued

TAXATION
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

DEFERRED TAX
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

IMPAIRMENT OF FIXED ASSETS
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs.
The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

PROVISIONS
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.
Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset.

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2023 - 7 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 30 September 2023
and 29 September 2024 67,765
AMORTISATION
At 30 September 2023 24,796
Charge for year 13,553
At 29 September 2024 38,349
NET BOOK VALUE
At 29 September 2024 29,416
At 29 September 2023 42,969

5. PROPERTY, PLANT AND EQUIPMENT
Fixtures
Plant and and Motor
machinery fittings vehicles Totals
£    £    £    £   
COST
At 30 September 2023 1,109 84,254 36,498 121,861
Additions - 1,536 - 1,536
At 29 September 2024 1,109 85,790 36,498 123,397
DEPRECIATION
At 30 September 2023 622 73,122 12,874 86,618
Charge for year 97 4,347 5,906 10,350
At 29 September 2024 719 77,469 18,780 96,968
NET BOOK VALUE
At 29 September 2024 390 8,321 17,718 26,429
At 29 September 2023 487 11,132 23,624 35,243

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.9.24 29.9.23
£    £   
Trade debtors 338,339 390,452
Other debtors 1 818
Prepayments 9,334 8,909
347,674 400,179

MISTRY MEDICAL SUPPLIES LIMITED (REGISTERED NUMBER: 06078259)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.9.24 29.9.23
£    £   
Trade creditors 375,251 461,908
Tax 50,264 53,054
VAT 6,196 20,453
Other creditors 29,143 2,719
Pension 352 207
Directors' loan accounts 251,035 264,093
Accruals and deferred income 5,007 5,627
717,248 808,061

8. RELATED PARTY DISCLOSURES

At 30 September 2024 the company owed the directors and shareholders the sum of £251,034 (2023 £264,092).

All other transactions with the directors and shareholders are deemed to be conducted under normal market conditions and/or are not material.




9. POST BALANCE SHEET EVENTS

There were no significant events up to the date of the approval of financial statements by the Board.